Abstract
The recurrence rate of resected gastric cancer with curative intent was around 20%. When early gastric cancer was excluded, the rate was around 30%. Peritoneal dissemination accounted for half the recurrences, and was followed by hematogeneous metastasis, including hepatic metastasis. Chemotherapy was the main treatment modality because the possibility of curative resection was very low. Systemic chemotherapies based on biochemical modulation, particularly CDDP/5-FU therapy, have been routinely performed. For localized diseases, loco-regional therapies like drug administration via hepatic artery and intraperitoneal administration have been also applied.
MeSH terms
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Cisplatin / administration & dosage
-
Doxorubicin / administration & dosage
-
Drug Administration Schedule
-
Epirubicin / administration & dosage
-
Etoposide / administration & dosage
-
Fluorouracil / administration & dosage
-
Humans
-
Immunologic Factors / administration & dosage
-
Irinotecan
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / secondary
-
Lymphatic Metastasis
-
Methotrexate / administration & dosage
-
Mitomycin / administration & dosage
-
Neoplastic Cells, Circulating*
-
Peritoneal Neoplasms / drug therapy*
-
Peritoneal Neoplasms / secondary*
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / pathology*
Substances
-
Antineoplastic Agents, Phytogenic
-
Immunologic Factors
-
Epirubicin
-
Mitomycin
-
Etoposide
-
Irinotecan
-
Doxorubicin
-
Cisplatin
-
Fluorouracil
-
Camptothecin
-
Methotrexate
Supplementary concepts
-
AMF protocol
-
CF regimen
-
EAP protocol
-
FAM protocol
-
FAP protocol
-
FPEPIR regimen